Browse the evidence

Periodic fasting (PF) improves albuminuria in patients with type 2 diabetes (T2D) and diabetic nephropathy (DN).

Implementing periodic fasting may be beneficial for managing albuminuria in patients with T2D.

The optimal SPAN combination of 8.0-9.4 h/day sleep, 42-104 min/day MVPA, and a DQS of 32.5-50.0 was associated with a 57% lower risk of major adverse cardiovascular events (MACE) (HR: 0.43; 95% CI: 0.30, 0.62).

Practitioners should encourage optimal sleep, physical activity, and nutrition combinations to reduce cardiovascular event risk.

A minimum combined variation of an additional 11 min/day of sleep, 4.5 min/day MVPA, and 3 DQS points was associated with 10% lower MACE risk (HR: 0.90; 0.88, 0.94).

Small improvements in sleep, activity, and diet can significantly reduce cardiovascular event risk.

Caffeine supplementation resulted in significantly higher mean velocity at 40, 60, 80, and 90% of 1RM for both back squat and deadlift exercises compared with placebo.

Caffeine can be used as an effective ergogenic aid to enhance performance in powerlifting.

Mean power was significantly greater with caffeine intake during the back squat at 60%, 80%, and 90% of 1RM.

Incorporating caffeine may improve power output during high-intensity powerlifting.

Caffeine intake led to lower ratings of perceived exertion (RPE) for back squat and deadlift exercises.

Caffeine can help athletes feel less exertion during heavy lifts, potentially improving performance.

Almost all powerlifters (>97.5%) incorporated varied practice, including barbell variations and accessory exercises.

Incorporating varied exercises can be beneficial for powerlifters' training regimens.

Progressive overload, intensity management, and flexible dieting are more effective and sustainable than other methods.

Practitioners should focus on progressive overload and flexible dieting for better results.

Cardiovascular training, when properly integrated, does not hinder muscle growth.

Incorporating cardiovascular training can be beneficial without compromising muscle growth.

Creatine supplementation is validated as a safe and effective ergogenic aid and is distinct from anabolic steroids.

Creatine can be safely used to enhance performance without the risks associated with steroids.

Higher adherence to whole food plant-based (WFPB) and vegan diets is significantly associated with lower BMI.

Encouraging adherence to WFPB and vegan diets may help individuals achieve lower body weight.

Fully plant-based diets (WFPB and vegan) have the healthiest Healthy Eating Index (HEI) scores and BMIs.

Promoting fully plant-based diets may lead to improved diet quality and health outcomes.

AOM use prior to BMS is associated with significantly higher weight loss until the day of surgery (1.37 vs. 0.05; p = 0.04).

Practitioners may consider AOMs as a beneficial preoperative strategy for weight loss in bariatric surgery candidates.

GLP-1 based medications can achieve an average weight loss of 24%.

Practitioners can expect significant weight loss with GLP-1 medications.

GLP-1 agonists positively affect multiple obesity-related complications.

GLP-1 agonists can be used to manage various obesity-related health issues.

GLP-1-agonists significantly reduce the risk of cardiovascular endpoints in patients with overweight or obesity without diabetes, with a Number Needed to Treat (NNT) of 44.

GLP-1-agonists may be considered for reducing cardiovascular risk in non-diabetic patients with obesity.

Lifestyle therapies, including weight loss and diet, are effective for managing obesity-related hypertension.

Encouraging weight loss and dietary changes can be beneficial for patients with obesity-related hypertension.

Incretin drug therapy can produce significant weight loss in properly selected individuals.

Clinicians should consider incretin therapy for weight loss in appropriately selected patients.

New dietary interventions are poised to overtake traditional strategies as the ideal approach to achieving sustained weight loss for obesity-associated hypertension patients.

Practitioners should consider implementing new dietary interventions for better weight loss outcomes in patients.

Bariatric surgery is the most effective treatment for obesity, yielding sustainable weight loss of about 20-30%.

Bariatric surgery should be considered for patients with obesity seeking significant weight loss.

GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.

Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.

Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.

Combination therapies may offer significant weight loss benefits similar to surgical options.

Pharmacotherapy is highly effective in reducing body weight and improving metabolic parameters.

Pharmacotherapy should be considered as a key component in obesity treatment plans.

Psychological support, including cognitive-behavioral therapy, increases patient adherence and improves long-term outcomes.

Incorporating psychological support can enhance treatment adherence and effectiveness.